patentgrepDocs Get an API key

C07K 14/8103

Exopeptidase inhibitors

Official title: {Exopeptidase (E.C. 3.4.11-19) inhibitors}

C07K14/8103 (Exopeptidase inhibitors) appears on 32 US grants and 36 published applications in this corpus.

Search patents in C07K

Granted patents: 32
Published applications: 36
Assignees: 32
Inventors: 130
Latest grant: 9 Sep 2025

Filings by year

C07K 14/8103: granted patents and published applications per publication year
Year	Granted patents	Published applications
1976	1	0
1977	0	0
1978	0	0
1979	0	0
1980	0	0
1981	0	0
1982	0	0
1983	0	0
1984	0	0
1985	0	0
1986	0	0
1987	0	0
1988	0	0
1989	0	0
1990	0	0
1991	0	0
1992	0	0
1993	0	0
1994	1	0
1995	0	0
1996	0	0
1997	2	0
1998	1	0
1999	3	0
2000	0	0
2001	3	0
2002	0	1
2003	2	0
2004	0	0
2005	0	0
2006	1	1
2007	0	0
2008	0	2
2009	0	2
2010	0	0
2011	1	2
2012	2	0
2013	0	2
2014	2	2
2015	0	2
2016	3	1
2017	2	0
2018	0	1
2019	0	2
2020	1	3
2021	1	2
2022	0	3
2023	2	7
2024	0	2
2025	4	1

By publication year. Applications have been published since 2001.

Recent patents

Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof9 Sep 2025US 12,410,237 B2Centre National De La Recherche Scientifique
Angiotensin i-converting enzyme (ACE) inhibitory peptides6 May 2025US 12,291,580 B2Thai Union Group Public Company Limited
Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses29 Apr 2025US 12,285,480 B2NantCell, Inc.
Methods for the treatment of COVID-19 comprising administering replication-defective adenoviruses encoding the SARS-CoV-2 spike glycoprotein and modified nucleocapsid protein29 Apr 2025US 12,285,481 B2NantCell, Inc.
Angiotensin I-converting enzyme (ACE) inhibitory peptides12 Sep 2023US 11,753,442 B2Thai Union Group Public Company Limited

Most cited

By later US patents